

LETTER

Open Access



# Effect of hydroxychloroquine on prevention of COVID-19 virus infection among healthcare professionals: a structured summary of a study protocol for a randomised controlled trial

Reihaneh Pirjani<sup>1\*</sup>, Tahereh Soori<sup>2</sup>, Ahmad Reza Dehpour<sup>3,4</sup>, Mahdi Sepidarkish<sup>5</sup>, Ashraf Moini<sup>1,6</sup>, Arshia Shizarpour<sup>7</sup> and Razieh Mohammad Jafari<sup>8</sup>

## Abstract

**Objectives:** Comparison of the effect of hydroxychloroquine with placebo to prevent infection from the COVID -19 virus among healthcare professionals

**Trial design:** Single centre, 2-arm, double-blind randomised (ratio 1:1) placebo-controlled trial

**Participants:** Treatment staff who are in contact with patients and have at least 3 shifts a week in Arash hospital affiliated with Tehran University of Medical Sciences, in Iran and who consent to participate in the study. Exclusion criteria include: History of COVID -19 virus infection, clinical symptoms such as fever, nausea, dyspnea and myalgia in the past two months, history of underlying diseases hypersensitivity to hydroxychloroquine and G6PD enzyme deficiency.

**Intervention and comparator:** Intervention group: Hydroxychloroquine 200 mg tablet of Amin Pharmaceutical. Control group: placebo which is completely similar in form and taste to 200 mg hydroxychloroquine tablet and is manufactured by the same factory (Amin Pharmacy). The dosage is two tablets daily, once a week for one to three months (based on the duration of the Coronavirus epidemic in Tehran).

**Main outcomes:** Confirmed COVID-19 virus infection using Polymerase chain reaction (PCR) test is the primary outcome. The time period for measuring the primary outcome is any infection within the trial period up to one month after taking the last dose.

**Randomisation:** The randomized block allocation method was developed using Stata version 15 software by an independent researcher, using a block size of six. Allocation to the two treatment groups will be conducted by this researcher using paper labels (random 10-digit codes) in a 1:1 ratio. The labels will be attached to the drug packages in order of randomization. Drug packages will be arranged in a box according to the randomization list.

(Continued on next page)

\* Correspondence: [pirjani@razi.tums.ac.ir](mailto:pirjani@razi.tums.ac.ir)

<sup>1</sup>Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

(Continued from previous page)

**Blinding (masking):** Participants and caregivers are blinded to group assignment and the data will be analyzed by an independent statistical expert who is unaware of the treatment allocation.

**Numbers to be randomised (sample size):** A total of 282 participants will be randomised with 141 participants to the Hydroxychloroquine each intervention group and 141 participants to the placebo control group

**Trial Status:** The protocol version number is 99-1-101-47091 and the approval ID is IR.TUMS.VCR.REC.1399.001 and recruitment began April 7, 2020, and is anticipated to be complete by August 7, 2020.

**Trial registration:** The name of the trial register is Iranian registry of clinical trial (IRCT), registration number is IRCT20120826010664N6, date of trial registration is April 7, 2020,

**Full protocol:** The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

**Keywords:** COVID-19, Randomised controlled trial, protocol, hydroxychloroquine, healthcare professionals, prevention

## Supplementary information

**Supplementary information** accompanies this paper at <https://doi.org/10.1186/s13063-020-04439-3>.

**Additional file 1.** Full study protocol.

## Acknowledgements

Not applicable.

## Authors' contributions

Study design and protocol development: RP, ARD, AM, RMJ, TS, MS. Data analysis: M S. Subject recruitment and follow up: RP, TS, ASH, MR, AM. Manuscript preparation: RP, MS, RMJ. Manuscript review and submission: RP, MS, ARD, AM. The author(s) read and approved the final manuscript.

## Funding

This research has been supported by a research grant No: 99-1-101-47091 from Deputy of Research affairs, Tehran University of Medical Sciences, Tehran, Iran.

## Availability of data and materials

Not applicable.

## Ethics approval and consent to participate

Ethics committee of Tehran University of Medical Sciences has approved the study, its ethical code is IR.TUMS.VCR.REC.1399.001 and approval was granted on March 22, 2020. I certify that this trial has received ethical approval from the appropriate ethical committee as described above. Written consent is obtained from participants to participate in the study.

## Consent for publication

Not applicable.

## Competing interests

The authors declare that they have no competing interests.

## Author details

<sup>1</sup>Department of Obstetrics and Gynecology, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran. <sup>2</sup>Department of Infectious Diseases, Arash Hospital, Tehran University of Medical Sciences, Tehran, Iran. <sup>3</sup>Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. <sup>4</sup>Experimental Medicine Research Center, TUMS, Tehran, Iran. <sup>5</sup>Department of Biostatistics and Epidemiology, School of Public Health, Babol University of Medical Sciences, Babol, Iran. <sup>6</sup>Reproductive Epidemiology Research Center, Royan Institute for Reproductive Biomedicine, Tehran, Iran. <sup>7</sup>School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. <sup>8</sup>Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.

Received: 19 May 2020 Accepted: 20 May 2020

Published online: 03 June 2020

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

